ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Interferon beta-1a

Also written as “Rebif®”, “RNF” and “Rebif”.

Its studies are mostly in Multiple Sclerosis · Multiple Sclerosis, Relapsing-Remitting · COVID-19 · Colitis, Ulcerative · Pneumonia, Viral, led by 7 companies.

Drug pageInterferon beta-1a: every studyMany companies study it; this page follows only the 53 they lead. All 82 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 13, 200553 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biogen230 open or runningphase 4since Sep 13, 2005Dec 15, 2004none ahead
Merck KGaA, Darmstadt, Germanyits history only210 open or runningphase 4since Feb 23, 2004Feb 23, 2004none ahead
Faron Pharmaceuticalsits history only30 open or runningphase 3since Nov 24, 2015Nov 24, 2015none ahead
Biocadits history only20 open or runningphase 3since May 29, 2015Jan 10, 2013none ahead
Cinnagenits history only20 open or runningphase 3since Jan 17, 2022Jul 14, 2018none ahead
Azidus Brasilits history only10 open or runningphase 1since Nov 13, 2009Nov 13, 2009none ahead
Trio Medicinesits history only10 open or runningphase 1since May 20, 2013May 20, 2013none ahead

Also a collaborator on its studies: Toray Industries, Pfizer, Gesellschaft für Therapieforschung mbH, Merck Serono S.P.A., Italy, Merck Serono S.A.S, France, EMD Serono Canada, Elan Pharmaceuticals, Merck Pte. Ltd., Singapore and Merck Serono International.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Biogen only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 8 studies since Dec 15, 2004.

  1. Oct 7, 2008Phase 4 study in Multiple Sclerosis, Relapsing-RemittingNCT00771043
  2. Oct 29, 2008Phase 3 study in Multiple SclerosisNCT00784836 · 3 enrolled · United States
  3. Jan 20, 2009Phase 3 study in Multiple SclerosisNCT00828204 · 95 enrolled · United States
  4. Jun 2, 20092 phase 4 studies in Multiple SclerosisNCT00913666, NCT00915460
  5. Jun 2, 2009Phase 1 study in Multiple SclerosisNCT00913250 · 96 enrolled
  6. Jun 2, 2009Phase 2 study in Multiple SclerosisNCT00912860 · 155 enrolled
  7. Jun 5, 2009Phase 3 study in Multiple SclerosisNCT00915577 · 74 enrolled
  8. Feb 17, 2010Phase 2 study in Multiple Sclerosis, Relapsing-RemittingNCT01071083 · 175 enrolled · United States, Germany, Spain
  9. May 6, 2010Phase 1 study in Healthy VolunteersNCT01119677 · 120 enrolled · United States
  10. Aug 5, 2010Phase 3 study in Multiple SclerosisNCT01181115 · 60 enrolled · China
  11. Jun 30, 2011Phase 1 study in HealthyNCT01416207 · 24 enrolled · China
  12. Dec 22, 2011Phase 1 study in Multiple SclerosisNCT01500408 · 110 enrolled · United States
  13. Oct 17, 2014Phase 1 study in Multiple SclerosisNCT02269930 · 30 enrolled · United States
  14. Jan 26, 2017Phase 4 study in Multiple Sclerosis, Relapsing-RemittingNCT03177083 · 80 enrolled · Portugal

TargetBeta

“A recombinant form of the endogenous cytokine human interferon (IFN) beta-1a, with antiproliferative, antiviral and immunomodulating activities”NCIt, by rule
“Interferon alpha/beta receptor agonist”ChEMBL 37, by rule

Studies

All 23 Biogen leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT03177083Multiple Sclerosis, Relapsing-Remitting · Portugal4CompletedOct 26, 202080
NCT02269930Multiple Sclerosis · United States1CompletedDec 201430
NCT01500408Multiple Sclerosis · United States1CompletedApr 2012110
NCT01416207Healthy · China1CompletedOct 201124
NCT01181115Multiple Sclerosis · China3CompletedOct 201160
NCT01119677Healthy Volunteers · United States1CompletedOct 23, 2010120
NCT01071083Multiple Sclerosis, Relapsing-Remitting · United States, Germany, Spain2CompletedNov 2011175
NCT00915577Multiple Sclerosis3CompletedApr 200674
NCT00915460Multiple Sclerosis4CompletedJun 2003408
NCT00913666Multiple Sclerosis4Completed121
NCT00913250Multiple Sclerosis1Completed96
NCT00912860Multiple Sclerosis2CompletedDec 2004155
NCT00828204Multiple Sclerosis · United States3CompletedJul 201095
NCT00784836Multiple Sclerosis · United States3TerminatedFeb 20093
NCT00771043Multiple Sclerosis, Relapsing-Remitting4WithdrawnAug 1, 20090
NCT00616434Active Ulcerative Colitis · United States, Canada, Czech Republic and more2CompletedMar 2010123
NCT00574041Multiple Sclerosis, Relapsing-Remitting · Australia4TerminatedFeb 200819
NCT00534261Multiple Sclerosis, Relapsing-Remitting · Belgium, Luxembourg, United Kingdom4Completed284
NCT00493116Multiple Sclerosis, Relapsing-Remitting · Australia, New Zealand4CompletedDec 200920
NCT00493077Multiple Sclerosis · Sweden4CompletedMay 20063
NCT00492466Multiple Sclerosis, Relapsing-Remitting · Finland4CompletedAug 200614
NCT00168766Multiple Sclerosis, Relapsing-Remitting · Belgium, Denmark, Finland and more4CompletedNov 2008345
NCT00099489Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Australia, Canada and more2CompletedFeb 200667

How it is read

Names in the registry

  • “Interferon beta-1a”, 11 entries
  • “Rebif®”, 7 entries
  • “RNF”, 5 entries
  • “Rebif”, 4 entries
  • “SNG001”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.